Kane Biotech Inc.

Kane Biotech Inc.

March 22, 2006 09:03 ET

Kane Biotech Appoints New President

WINNIPEG, MANITOBA--(CCNMatthews - March 22, 2006) - Kane Biotech Inc. (TSX VENTURE:KNE), a leading biofilm company, is pleased to announce the appointment of Gord Froehlich as President.

Mr. Froehlich, a 30 year veteran of managing and commercializing biotechnology ventures, brings leadership and vision as Kane Biotech charts an aggressive growth and development strategy. Prior to his appointment Mr. Froehlich was Kane's Vice-President, Business Development. He has also held senior leadership positions in the biotechnology industry as Vice-President of Monsanto Canada.

Mr. Froehlich succeeds Mr. Marcus Enns, who is stepping down as President, but will remain an officer of Kane Biotech.

"Gord has proven himself to be a strong leader with broad knowledge, and a thorough understanding of the licensing and commercialization of biotechnology products", stated outgoing President, Mr. Enns. "I am very pleased to see Kane moving forward under Gord's direction."

"Kane Biotech is in an exciting stage of development, with promising products in two large underserved markets," stated Mr. Froehlich. "I am enthusiastic to be leading the Company and I look forward to directing the Company's growth into the future."

Kane Biotech recently announced positive results of an important animal study with its lead catheter product KBI-5898 and continues to aggressively pursue its commercialization strategy for KBI-5898. Infections caused by urinary catheters cost the United States healthcare system over US$1 billion per year. In addition, the Company is developing an oral care product based on its novel CSP technology for the prevention of dental plaque. The U.S. dental market is over US$70 billion per year.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information